Novo Nordisk Hit by U.S. Delay to New Insulin Drug

Danish drugmaker Novo Nordisk , the world's biggest insulin maker, said on Friday that U.S. health regulators had extended their review of its new ultra-long-acting insulin Tresiba, or degludec, to consider further data.

The unexpected delay is a disappointment since degludec is a pivotal new product with which Novo hopes to consolidate its position in the fast-growing diabetes market.

A decision on the medicines is now expected on Oct. 29, when the verdict will also be delivered on a related combination production called Ryzodeg, or degludecplus. Both drugs are designed to treat type 1 and type 2 diabetes.

The U.S. Food and Drug Administration asked for further data clarification and analyses, and the company has submitted a substantial amount of additional data.

"Due to the size and timing of these submissions the FDA considers them as major amendments to the (new drug applications)," the company said in a statement, adding that the agency had not requested additional clinical trials.

Analysts at Danske Bank said that a U.S. launch in 2012 now seemed unlikely but they did not believe the likelihood of approval had declined, so the delay should not have a big impact on valuation.

Tim Race of Deutsche Bank said the news would inevitably dampen sentiment towards Novo's highly rated shares, which trade on 22.5 times expected 2012 earnings, but he agreed the financial implications were limited.

"We see the delay as unexpected and disappointing, but ultimately not unusual," Race said in a research note.

Tresiba and Ryzodeg are seen as strong new competitors in the long-acting, or basal, insulin market, which has long been dominated by Sanofi's Lantus. Competition is hotting up in the space, with Eli Lilly also having a promising new contender in development.

Novo Nordisk has also filed for approval of the two products with the European Medicines Agency and regulators in Japan, Canada, Switzerland and some other countries.

It first filed for approval in the United States in September last year.

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.

Photo
10.02.2025 • News

Johnson Matthey, Bosch to Partner on Hydrogen Technology

UK sustainable technologies group Johnson Matthey (JM) and German engineering giant Bosch have agreed on a long-term collaboration to develop and produce high-performance catalyst-coated membranes (CCMs) for use in hydrogen fuel cells.